Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
Line 1: | Line 1: | ||
− | == |
+ | == Background == |
+ | ===Pathophysiology=== |
||
⚫ | |||
⚫ | |||
− | == Investigations == |
||
+ | ==Diagnosis== |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
⚫ | |||
− | * Eculizumab |
||
⚫ | |||
+ | **[[Eculizumab]] to inhibit complement |
||
[[Category:Hematology]] |
[[Category:Hematology]] |
Revision as of 07:29, 15 August 2020
Background
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment
- Eculizumab to inhibit complement